Sign in
Taking people in PolandPhase 3

Gene-guided cladribine drug combinations for acute myeloid leukemia

Tests gene-guided cladribine combinations in people with acute myeloid leukemia.

Key facts

Who runs it
Medical University Of Lodz
Where
Bialystok, Brzozów, Bydgoszcz, Chorzów, Cracow, Gdansk, Gdynia, Katowice, Lodz, Lublin, Olsztyn, Poznan, Szczecin, Torun, Warsaw, and Wroclaw, PolandSee the 18 sites
Registry title
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia
Status
Recruiting
Phase
Phase 3
People taking part
520 people, planned
Started
23 Oct 2024
Expected to end
7 May 2029
Type of study
Interventional
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed acute myeloid leukemia who are fit enough for intensive chemotherapy.

Age
18 years or older and under 66 years.
Sex
Women and men can join.
Disease stage
Acute myeloid leukemia diagnosed by the WHO 2016 criteria. General condition ECOG 2 or better and HCT-CI comorbidity score of 3 or lower.
Biomarker or test result
The trial has separate arms for CBF-AML, for AML with FLT3 gene mutations, and for other AML.

Main reasons for not taking part

  • Acute promyelocytic leukemia
  • Pregnancy or breastfeeding
  • Other active cancer
  • HIV infection or active hepatitis B or C infection
  • Organ failure that rules out intensive chemotherapy

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Acute Myeloid Leukemia diagnosed according to the WHO 2016 criteria
  • Age ≥ 18 and <66 years on the date of signing the informed consent form to participate in the study
  • General condition according to the ECOG scale ≤ 2
  • HCT-CI comorbidity index score ≤ 3
  • Informed, written consent to participate in the study
  • Consent to the use of effective contraception during the study with the use of contraception in both women and men
  • Negative serum or urine pregnancy test in women of childbearing age

Who cannot take part

  • Other active cancer disease
  • HIV infection
  • Active infection with hepatitis B or C virus
  • Organ failure which is a contraindication to the use of intensive chemotherapy
  • Known hypersensitivity to any of the preparations used in the treatment
  • Acute Promyelocytic Leukemia
  • Pregnancy and breastfeeding
  • Other not described above abnormalities that exclude the patient from the study based on the Investigator's assessment

Where in Poland

  • Uniwersytecki Szpital Kliniczny w BialymstokuBialystok, PolandTaking people
  • Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.MarkiewiczaBrzozów, PolandTaking people
  • Szpital Uniwersytecki nr 2 im dr Jana Biziela w BydgoszczyBydgoszcz, PolandTaking people
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali MiejskichChorzów, PolandTaking people
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W KrakowieCracow, PolandTaking people
  • Szpital Specjalistyczny Im. Ludwika Rydygiera W Krakowie Sp. z o.o.Cracow, PolandTaking people
  • Uniwersyteckie Centrum KliniczneGdansk, PolandTaking people
  • Szpitale Pomorskie Sp z o oGdynia, PolandTaking people
  • Samodzielny Publiczny Szpital Kliniczny Imienia Andrzeja MieleckiegoKatowice, PolandTaking people
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w LodziLodz, PolandTaking people
  • Samodzielny Publiczny Szpital Kliniczny nr 1 w LublinieLublin, PolandTaking people
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych I Administracji Z Warminsko-Mazurskim Centrum Onkologii W OlsztynieOlsztyn, PolandTaking people
  • Uniwersytecki Szpital Kliniczny w PoznaniuPoznan, PolandTaking people
  • Uniwersytecki Szpital Kliniczny Nr 1 Im. Prof. Tadeusza Sokolowskiego Pum W SzczecinieSzczecin, PolandTaking people
  • Wojewodzki Szpital Zespolony im. L. Rydygiera w ToruniuTorun, PolandTaking people
  • Instytut Hematologii I TransfuzjologiiWarsaw, PolandTaking people
  • Medical University of WarsawWarsaw, PolandTaking people
  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandTaking people

About the trial

What the trial wants to find out

Comparison of efficacy (measured as event-free survival; EFS) of induction treatment including:

Read full original descriptionShow less

(i) cladribine in combination with daunorubicin, cytosine arabinoside and gemtuzumab ozogamicin (DAC+GO protocol) in CBF-AML patients compared to induction therapy according to DAC protocol;

(ii) cladribine in combination with daunorubicin, cytosine arabinoside and midostaurin (DAC+M protocol) in AML patients with FLT3 gene mutations compared to induction treatment according to the DA+M protocol;

(iii) venetoclax in combination with cladribine, daunorubicin and cytosine arabinoside (DAC+Ven protocol) compared to DAC protocol plus placebo in other AML patients

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia
Plain-language title
Gene-guided cladribine drug combinations for acute myeloid leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
4 November 2026